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Abstract 
Spherical mesoporous nanoparticles (MNPs) with a diameter of ~100 nm were 
synthesised via a sol-gel method in the presences of organic template (with and without 
fluorescein dye encapsulation). The template molecules were removed by acidic 
extraction to form a regular pore lattice structure. The nanoparticle size and morphology 
were analysed using transmission electron microscopy and dynamic light scattering 
analysis. The MNPs were further characterised by zeta potential, nitrogen adsorption 
measurements and infra-red spectroscopy. The interior pores had an average diameter of 
~3 nm and were loaded with an endothelial-independent vasodilator, sodium 
nitroprusside (SNP). The optimal drug loading and drug release was determined in high 
potassium physiological salt solution using dialysis and atomic absorption spectroscopy. 
We demonstrate that the initial instantaneous release is due to the surface desorption of 
the drug followed by diffusion from the pores. Furthermore, these drug loaded MNPs 
(with and without fluorescein dye encapsulation) were added to viable aortic vessels and 
release in real-time was observed, in-vitro. MNPs and loaded with and without SNP were 
incubated with the vessel (at 1.96×1012 NP mL-1) over a 3 h time period. The real-time 
exposure to unloaded MNPs resulted in a small attenuation in constriction that occurred 
after approximately 1 h. In contrast, MNPs loaded with SNP led to a rapid relaxation of 
aortic vessels that was sustained over the 3 h period (p<0.001).
Keywords: 
Mesoporous nanoparticles,  sodium nitroprusside,  drug release,  aortic vessels,  vascular 
function, vasodilator.
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1. Introduction     
Progress in nanoparticle fabrication techniques has enabled the tailoring of nanoparticle 
properties for the development of innovatively designed biological drug delivery vehicles 
[1-3]. Orally and intravenously administered drugs circulate throughout the body and 
may have a number of systemic side effects, often leading to poor efficiency of the drug 
[4]. Consequently, there is a drive for the development of new drug delivery systems. In 
particular, mesoporous nanoparticles (MNPs) can be fabricated using colloidal methods 
with small diameters that are able to enter cells. Regular pore structure is produced during 
the surfactant template synthesis method [5]. The resulting MNPs have high surface to 
volume ratio’s with pore channels that can be loaded with guest molecules. The exterior 
surface is available for functionalisation to enable targeted therapy of intracellular 
structures [6]. Furthermore, these particles have been used for diagnostic imaging and 
cellular localisation by confocal microscopy and flow cytometry by incorporation of 
fluorescent dye molecules within the MNPs silica framework [7]. Once the nanoparticles 
have been drug loaded, the release is governed by constrained pore diffusion enabling 
these particles to be utilised for slow drug release applications [8, 9]. Previous studies 
have used MNPs as hosts (such as MCM-41and SBA-15) and loaded with guest 
molecules (such as drugs, enzymes, DNA and luminescent dyes) to produce effective 
systems in which the host-guest interaction plays a vital role in their application [10]. 
The ordered pore network of MNPs allows fine control of the drug loading and 
release kinetics, while the large surface area allows adsorption of the required dosage of 
drug [5]. Release kinetics has been demonstrated from MNPs using luminescent 
molecules and ibuprofen [9, 11-14]. One study showed that 80 % of ibuprofen was 
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released after only 50 min from MNPs with pore size of 3.4 nm and particle diameter of 
50 µm [15]. Another study demonstrated that it took 31 h for the release of 60 % of 
ibuprofen loaded into MNPs (diameter 950 nm and pore size of 2.5 nm). There has been 
an abundance of studies showing that MNPs are internalised into the cytoplasm of 
mammalian cells with low cytotoxicity (LD50 values greater than 1mg mL-1) 
demonstrating their biocompatibility [16].
The aortic vessel is the largest artery in vertebrates and plays an important role in 
the transport of blood and the maintenance of blood pressure (Fig. 1). Arteries are 
comprised of three layers, an endothelial layer facing the lumen, a smooth muscle layer, 
and an outer adventitial layer [17]. Vessel viability and the integrity of the endothelial and 
smooth muscle cell layers can be verified by examining vascular responses to vasodilator 
and vasoconstrictor agonists [18]. A major vasodilator released naturally by endothelial 
cells is nitric oxide (NO) and is important in the maintenance of vessel diameter. 
Reduced bioavailability of NO has been demonstrated in a number of vascular related 
conditions, including diabetes and hypertension [19]. The development of nanoparticles 
that can deliver sustained and controlled release of NO could have enormous impact on 
human health. One approach has been the development of silica hydrogel nanoparticle 
matrices, whereby the entrapped NO molecules are released when exposed to moisture 
[20]. Sodium nitroprusside (SNP) is an endothelial independent vasodilator that causes 
relaxation of the smooth muscle cells by delivery of NO, which is a labile ligand, 
contained within the SNP molecular complex [21-23]. In this study, we report for the first 
time the in vitro real-time vasodilator action of SNP on arterial vessels delivered via 
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MNPs. Controlled release of SNP from MNPs is a promising avenue for the development 
of therapeutic intervention in cardiovascular disease.
2. Materials and methods
2.1. Materials
Fluorescein isothiocyanate (FITC), (3-aminopropyl)trimethoxysilane (APTMS), 
tetraethyl orthosilicate (TEOS), hydrochloric acid (HCl, 37 %) and sodium nitroprusside 
(SNP) were purchased from Sigma-Aldrich. Hexadecyltrimethyammonium bromide 
(CTAB), anhydrous dimethylformamide (DMF), sodium hydroxide (NaOH) and 
methanol (MeOH) were purchased from Fisher-Scientific. Salt solutions were prepared 
using sodium chloride (NaCl), potassium chloride (KCl), magnesium sulphate 
heptahydrate (MgSO4.7H2O), potassium phosphate monobasic (KH2PO4), calcium 
chloride (CaCl2.2H2O), ethylenediaminetetraacetic acid dipotassium salt dihydrate 
(K2EDTA.2H2O) purchased from Fisher-Scientific. 
Physiological Salt Solution (PSS) was prepared using the following chemical 
composition [mM]:  119 NaCl, 4.7 KCl, 1.2 MgSO4.7 H2O, 25 NaHCO3, 1.17 KH2PO4, 
0.03 K2EDTA.2H2O, 5.5 glucose and 1.6 CaCl2.2H2O; pH 7.4.  Potassium Physiological 
Salt Solution (KPSS) was prepared using the following chemical composition [mM]: 78.2 
NaCl, 60 KCl, 1.2 MgSO4.7 H2O, 25 NaHCO3, 1.17 KH2PO4, 0.03 K2EDTA.2H2O, 5.5 
glucose and 1.6 CaCl2.2H2O; pH 7.4 as previously described by Farooq et al [24].    
2.2. Synthesis of non-dye encapsulated mesoporous nanoparticles 
Mesoporous silica nanoparticles (MNPs) were synthesised using a modified 
template directed self-assembly method published by Slowing et al without the 
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incorporation of FITC dye molecules [25]. Briefly, anhydrous DMF (5 mL) was mixed 
with APTMS (50 µL). CTAB (1 g) was dissolved in H2O (480 mL) and 2 M NaOH 
solution (3.5 mL) was added and stirred at 80 °C. TEOS (4 mL) was added followed by 
the addition of the APTMS mixture (500 µL). The resulting mixture was stirred 
vigorously at 80 °C for 2 h producing an opaque white suspension. The MNPs were 
collected and washed with MeOH by centrifugation (14,000 rpm/ 15 min) several times. 
The surfactant template (CTAB) was extracted from the as-synthesised product by 
refluxing the product in MeOH (200 mL) and concentrated HCl (2 mL) for 24 h. The 
MNPs were washed using the same procedure as before. The acid extraction step was 
repeated twice.
2.3. Synthesis of dye encapsulated mesoporous nanoparticles
Fluorescein isothiocyanate encapsulated mesoporous nanoparticles (FITC MNPs) 
were synthesised via the same method as the MNPs except that FITC (2.5 mg) was added 
to the mixture of anhydrous DMF and APTMS and then stirred for 3 h. [25]. The resulting 
product was a yellow suspension.
2.4. Characterisation of mesoporous nanoparticles
The MNPs hydrodynamic size and zeta potential were determined by dynamic 
light scattering (DLS) and laser Doppler velocimetry respectively (Malvern Zetasizer 
nano ZS instrument). The zeta potential was determined for MNPs in both distilled water 
and KPSS. The MNP sizes were further confirmed using scanning electron microscopy 
(SEM, JEOL 5600LV SEM) and transmission electron microscopy (TEM, Philips 
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TechnaiTM 12 Biotwin TEM). Nitrogen adsorption isotherms at -196 °C were measured 
with a Micromeritics ASAP 2020 instrument. Samples were degassed at 200 °C for 12 h 
prior to analysis. The Brunauer-Emmett-Teller (BET) surface area was calculated in the 
range of relative pressures 0.03-0.05 (p/ po). The pore size distributions were determined 
by the Barrett-Joyner-Halenda (BJH) method from the desorption branch of the isotherms. 
The infra-red analysis was used for confirmation of template removal (Nicolet Avatar 360 
FT-IR). Fluorescence spectroscopy was used to determine the encapsulation of dye 
molecules within the MNPs by producing a calibration plot of know concentrations of 
FITC dye molecules (Hitachi fluorescence spectrophotometer F-2500).  
2.5. Drug loading efficiency
Drug loading efficiency was calculated using equation 1 below [26]. 250 mg of MNPs 
with and without dye molecules were suspended into 25 mL of the SNP methanol 
solution (1×10-5 mol dm-3) and stirred for 48 h to facilitate drug uptake. The solution was 
centrifuged to separate the nanoparticles loaded with SNP. The supernatant was analysed 
using inductively coupled plasma atomic emission spectroscopy (ICP-AES) to measure 
concentration of Fe as a single atom is present per SNP molecule. The loading efficiency 
percentage was calculated as the ratio of difference between the initial drug concentration 
and the drug concentration in the supernatant (free drug) to the initial drug concentration, 
as followed 
Drug loading efficiency (%) = Total drug-[Free drug] [Total 
drug] x 100 (1)
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2.6. Release profile of sodium nitroprusside from mesoporous nanoparticles
For the release profile, MNPs-SNP (128 mg) was dispersed in 4 mL of KPSS and 
placed in small vial and covered with dialysis tubing on the top. The resulting vial was 
placed in a glass bottle containing KPSS (15 mL) with the dialysis membrane immersed 
in the solution. The release of SNP was examined by taking 1 mL aliquots of the solution 
contained within the beaker and replacing the solution with 1 mL of KPSS at regular time 
intervals. This process was repeated for FITC MNPs under the same conditions. The 
concentration of SNP within the aliquots was quantified by measuring the concentration 
of Fe with ICP-AES. Initially, the method was validated by ascertaining linearity of 
standard curves; five standard curves of known concentrations (3.4×10-8, 1.7×10-7, 
3.4×10-7, 1.7×10-6, 3.4×10-6 mol dm-3) of SNP in diluted KPSS (1:5 ratio of KPSS to 
water) were calibrated. The stability of the auto-sampler was established with five 
replicates of each sample. 
2.7. Vascular functional studies
 The thoracic aortic arteries of male Wistar rats were used for the in vitro studies 
(n=13  animals;  one  vessel  from each  animal).  The  rats  of  approximately  150-250  g 
weight  were  humanly  killed  by  stunning  followed  by  cervical  dislocation  following 
institutional  approval  and  in  accordance  with  guidelines  issued  by  the  European 
Commission Directive 86/609/EEC. The perivascular adipose tissue was removed from 
the  vessel  while  being gassed (95 % O2:  5  % CO2)  in  cold  PSS,  as  it  can attenuate 
contraction. The vessels was dissected into 3-4 mm aortic rings and mounted in an organ 
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bath system filled with PSS solution (35 oC) by threading the rings between a U-shaped 
hook and ascending wire attached to a micrometer, Fig. 2. The tension between the two 
wires was recorded using Labchart 6 (Powerlab, AD Instruments, UK). The aortic rings 
were placed under a constant 2 g tension throughout the experimentation as preliminary 
results have determined this to be the optimal tension value. Vessels were equilibrated for 
approximately 1 hour, followed by pre-constriction with  high K⁺ (60 mM, KCl) to test 
vessel viability and achieve stable contraction, as previously described by Farooq et al 
[24].  Responses to SNP were examined by adding cumulative doses of SNP (0.01-100 
µM) as a control.  MNPs  (1.96×1012 NP mL-1) and FITC MNPs  (1.96×1012 NP mL-1) 
were incubated with constricted vessels over a 3 h period. The number of nanoparticles 
per mL was determined by calculating the volume and density of a sphere with a diameter 
of 100 nm and finally the mass of a mesoporous nanoparticle; the density of mesoporous 
silica was 0.814 g cm-3[27].  
2.8.  Release  of  sodium  nitroprusside  from  mesoporous 
nanoparticles in vitro
The effect of the SNP loaded MNPs and FITC MNPs was examine by addition of 
1.96×1012 NP mL-1 to preconstricted vessels using the approach described above.
2.9. Transmission electron microscopy
Vessels tested in the release studies were fixed immediately after the functional 
studies, using 2.5 % glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.3) for 2 h at 
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22 ˚C. The samples were postfixed with reduced osmium (OsO4 1 % + K4Fe(CN)6 1.5 %) 
for 1 h, then dehydrated in a series of alcohols, infiltrated with TAAB LV resin and 
polymerized for 24 h at 60 ˚C, as previously described (Akbar et al. [28]). Ultrathin 70 
nm sections were cut with Leica ‘Ultracut S’ ultramicrotome and placed on formvar 
carbon coated TEM copper grids (Agar Scientific). The samples were observed using a 
Tecnai 12 Biotwin TEM at 80 kV as previously described by Farooq et al. [24].               
2.10. Statistical analysis
Data are expressed as mean ± standard error of mean (S.E.M.) with ‘n’ 
representing the number of vessels. Dilator responses are expressed as percent relaxation. 
Concentration response curves were assessed using statistical package for the social 
sciences (SPSS; version 19). The difference between groups at a given concentration was 
tested by one way analysis of variance (ANOVA) with Bonferroni corrections. Statistical 
significance is taken as P<0.05 as previously described by Farooq et al [24].              
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3. Results and discussion 
3.1. Mesoporous silica nanoparticles 
The SEM images in Fig. 3 confirm that particles produced have a narrow size 
distribution with an average diameter of 95±13 nm for MNPs (Fig. 3A) and 109±18 nm 
for the FITC MNPs (Fig. 3B). The TEM images showed that the MNPs (Fig. 4A) and 
FITC MNPs (Fig. 4B) were mainly spherical in shape with some variation in the size 
distributions. The particles had regular, parallel-aligned pore channels confirming the 
successful removal of the template using the acid extraction method. DLS measurements 
showed that the average hydrodynamic diameter of the as-synthesised MNPs was 182.9 
nm and the FITC MNPs was 183.9 nm with a polydispersion index of 0.49 and 0.4 
respectively (Table 1). A polydispersity index larger than 0.1 indicates the presence of 
aggregated particles. This would explain the large differences between the sizes 
determined by TEM and DLS. In addition, it is well known that the size determined by 
DLS is overestimated compared to size determined by TEM. Equally the zeta potential 
measurement for colloidal stability for particles to remain individual should be no less 
than -30mV, -13.8 demonstrates that there is potential for aggregation.  The template 
extracted MNPs and FITC MNPs were stable in water and high potassium salt solution 
(KPSS) as demonstrated with the zeta potential measurements (Table 1, Fig. S1). 
Furthermore, when template extracted MNPs were placed in KPSS the hydrodynamic 
diameter increased to 247.3 nm from 182.9 nm with the zeta potential values increasing 
to -13.8 mV from -30.0 mV, higher ionic strength solution leads to a smaller electrical 
double layer thickness, weaker electrostatic repulsive force, and subsequently larger 
hydrodynamic size. Similar behaviour was shown for the FITC MNPs in KPSS media 
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with the average hydrodynamic diameter increasing to 227.8 nm from 183.9 nm, along 
with the increase in the zeta potential values to -15.6 mV from –30.0 mV. 
The Fourier transform infra-red (FTIR) spectroscopy confirms that the CTAB 
template has been successfully removed (Fig. 5), as the characteristic two sharp peaks of 
the organic surfactant at 2853 cm-1 and 2923 cm-1 were diminished. 
The amount of dye molecules encapsulated within the silica framework of the 
MNPs was quantified with fluorescence spectroscopy. The fluorescence spectra of known 
concentrations of FITC were used to produce a calibration graph (Fig. S2). The excitation 
wavelength of FITC is 490 nm with an emission at 520 nm. The dye molecules 
encapsulated within the MNP were quantified by analysing the amount of dye molecules 
within the supernatant after centrifugation from the reaction media. Thus, the dye 
concentration within the MNPs was calculated by subtracting the concentration within the 
supernatant from the actual concentration of dye used (Table 2). The mass of FITC dye 
molecules within FITC MNPs was determined to be 2.48 mg. The FITC MNPs 
demonstrated a strong fluorescent signal (Fig. S3). 
The nitrogen adsorption and desorption of the MNPs follows the general 
Langmuir isotherm trend of mesoporous materials (Fig. 6) indicating monolayer 
adsorption of gas within the capillaries of the pores. From the gas adsorption analysis it 
was possible to determine that the silica MNPs have a pore diameter of 2.9 nm as shown 
in the pore size distribution graph (insert in Fig. 6A). The overall surface area was 
determined as 853.3 ± 9.0 m²g-1 confirming successful synthesis of high porosity 
particles. FITC MNPs has a surface area of 1154.5±2.1 m²g-1, which is larger than the 
silica MNPs, while the insert confirm the pore size to be 2.8 nm, similar to the silica 
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MNPs (Fig. 6B). All the isotherms indicate that ordered mesopores are present in the 
samples (the step at ~0.4 p/ po). 
3.2. Sodium nitroprusside release from mesoporous 
nanoparticles
The concentration of SNP was calculated from iron concentration which 
originated from the SNP drug and is shown in Table 3. The drug loading efficiency of the 
MNPs was determined to be 86.30 % whilst for the FITC MNPs it was 96.46% for 
250mg of the particles, indicating that nearly all the SNP drug was adsorbed when soaked 
in a concentration of 1×10-5 mol dm-3 SNP. There was a higher amount of drug adsorption 
by the FITC MNPs as there may be residual amine functional groups from the dye 
coupling reaction causing electrostatic attraction of SNP on the pore surface. 
The release rate of SNP from MNPs and FITC MNPs was investigated (Fig. 7). 
The time course of SNP release demonstrates that there is a rapid initial release for both 
types of MNPs over 10 min, this is expected due to the large concentration gradient but 
also due to some desorption on the particle exterior surface. From 10 min to 180 min 
there is a shallow gradient in the graph indicating slow release.
3.3. Detection of mesoporous nanoparticles within vascular 
tissue
In the present study, we demonstrate that the exposure of viable aortic vessels to 
MNPs and FITC MNPs of approximately 100 nm leads to their internalisation into the 
cytoplasm of the endothelial cells that line aortic vessels as shown in the TEM cross 
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section image in Fig.8. No particles were observed in the nucleus of the cells, elastic 
lamina, smooth muscle or adventitial layers.  
3.4. Sodium nitroprusside release from mesoporous 
nanoparticles in vitro
MNPs and FITC MNPs at 1.96×1012 NP mL-1 concentration were placed in the 
organ-bath system. The trend observed for the vasodilation of aortic vessels when 
incubated in MNPs loaded with SNP led to a significant reduction in constriction (Fig. 9). 
Furthermore, the constriction level was sustained for the control over a 3 h period. The 
real-time exposure of aortic vessels to FITC MNPs at 1.96×1012 NP mL-1 has a similar 
observable constriction level as the control over a 3 h time period (Fig. 10). The FITC 
MNPs loaded with SNP leads to a rapid relaxation of aortic vessels however, the 
relaxation was sustained over 120 min, thereafter followed by re-constriction. The 
statistical analysis confirms that the relaxation is significant for the SNP loaded FITC 
MNPs (Table 4).         
The dosage of MNPs added to the aortic vessels was 1.96×1012 NP mL-1 was the 
same concentration used in our previous study in which we tested non-porous silica 
nanoparticles (71±6 nm) [24]. In line with our previous observations with non-porous 
silica nanoparticles, the MNPs and FITC MNPs had no detriment to the endothelial-
independent vasodilation indicating good biocompatibility.  This is in good agreement 
with the literature where human cervical cancer cells (HeLa) were exposed to 100 µg mL-
1 of FITC MNPs and no difference between the control and the FITC MNPs cell growth 
profile were shown thus confirming they are not cytotoxic [25]. 
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Data from the in vitro real-time release studies were used to construct percentage 
relaxation graphs to SNP from MNPs (shown in Fig. 9B). There was no statistically 
significant difference over the 3 h exposure time period between the KPSS control and 
high concentration of MNPs (Table 4). Furthermore, the exposure of viable aortic vessels 
to MNPs loaded with SNP led to a rapid relaxation of the vessels. The MNPs loaded with 
SNP led to an initial sharp release of SNP within the first 20 min leading to 57.74 % 
relaxation. The maximum relaxation was 77.08 % and was reached at 125 min. 
Similarly, for the percentage relaxation graphs of MNPs, there was no statistically 
significant affect over the 3 h exposure time period between the KPSS control and FITC 
MNPs (Fig. 11B). Also, the MNPs loaded with SNP, led to a rapid relaxation of the 
vessels. The FITC MNPs loaded with SNP led to an initial sharp release of SNP within 
the first 20 min leading to 61.93 % relaxation. The maximum relaxation was 64.16 % and 
was reached at 35 min. 
In order to calculate the SNP release in real-time under physiological conditions, a 
calibration plot of known concentrations of SNP against relaxation was constructed (Fig. 
11). The logarithm equation, determined from the calibration plot, allowed for the 
calculation of SNP concentration released at a given time (Table 5). The calculated SNP 
release from the MNP with and without dye estimated from the calibration plot using the 
in vitro studies showed that the concentration of SNP after 180 minutes was similar to the 
release study in the dialysis tubing supernatant determined with atomic absorption 
spectroscopy (Table 6).  There was a lower concentration in vitro which is expected as the 
relaxation occurs from the dissociation of the NO ligand from the SNP, which diffuses 
through to the smooth muscle cells of the vessel.
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4. Conclusions
In conclusion, we have designed a drug delivery system allowing the release of a model 
drug - sodium nitroprusside (SNP agonist) from the mesoporous matrix. MNPs with an 
average size of 100 nm were used in the experiments in pure form or after encapsulation 
of a fluorescein isothiocyanate dye (FITC MNPs). The drug-loaded particles were added 
to isolated aortic vessels to record the real-time release profile, ex vivo.  Vessel relaxation 
was evident over a 3 h duration of the incubation period for both MNPs and FITC MNPs. 
We have created a biocompatible slow release drug delivery vehicle that can deliver 
sustained and controlled release of SNP. SNP delivers NO which acts on the smooth 
muscle cells causing vasodilation and is currently utilised in clinical practice to treat 
hypotension. These particles possess great potential as a novel drug delivery platform for 
therapeutic applications in the future for treatment of cardiovascular disease, particularly 
in preventing SNP overdose, which can be very dangerous for patients. Furthermore, 
FITC labelling of the MNPs could enable simultaneous imaging and therapy in the future. 
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FIGURE CAPTION 
Figure 1: Graphical illustration of a cross-section of the aortic vessel.
Figure 2:  Scanning electron microscope image of A) mesoporous nanoparticles and B) 
fluorescein isothiocyanate encapsulated mesoporous nanoparticles.
Figure 3:  Transmission electron microscope image of A) mesoporous nanoparticles, B) 
side-view of the mesopore channels and C) front-view of the mesopores. 
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Figure 4: FTIR spectra of A) MNP and B) FITC MNP, where the solid lines represent 
template intact and dashed are template removed.
22
Figure 5:  Nitrogen sorption isotherm for gas adsorption (diamond curve) and desorption 
(circle curve) of A) mesoporous nanoparticles and B) fluorescein isothiocyanate 
mesoporous nanoparticles. 
Figure 6:   Schematic illustration of the interaction between sodium nitroprusside and the 
mesopore channel. 
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Figure 7: Release profile of sodium nitroprusside from mesoporous nanoparticles using 
atomic absorption spectroscopy. 
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Figure 8: TEM images of sections of fixed aortic vessels after incubation with a) 
mesoporous silica nanoparticles and b) fluorescein isothiocyanate incorporated 
mesoporous silica nanoparticles.
Figure 9: The influence of sodium nitroprusside loaded mesoporous nanoparticles at A) 
high concentration on constricted aortic vessels in real-time. B) The influence of sodium 
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nitroprusside loaded mesoporous nanoparticles on endothelium-independent vasodilator 
responses.  ‘n’ is number of vessels. 
Figure 10: The influence of sodium nitroprusside loaded FITC mesoporous nanoparticles 
at A) high concentration on constricted aortic vessels in real-time. B) The influence of 
sodium nitroprusside loaded fluorescein isothiocyanate encapsulated mesoporous 
nanoparticles on endothelium-independent vasodilator responses.  ‘n’ is number of 
vessels. 
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Figure 11:  Calibration spectra of endothelium-independent vasodilator response against 
known concentrations of sodium nitroprusside. 
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TABLE 1:  Hydrodynamic size and stability measurements of mesoporous 
nanoparticles, in water and high potassium physiological salt solution.
Nanoparticles 
type
Primary diameter a
(nm)
Hydrodynamic 
diameterb
(nm)
ζ potential
(mV)
In water In KPSS
In 
water
In KPSS
MNPs 95±13 182.9 247.3 -30.0 -13.8
FITC MNPs 109±18 183.9 227.8 -30.0 -15.6
a Mean (±SD) diameter determined by SEM.
bMean PCS measurement.
TABLE 2:  Quantification of dye molecules within the nanoparticles.
Fluorescence 
intensity (a.u.)
Dye 
concentration 
(mol dm-3)
Moles of Dye
(mol)
Mass of dye 
(mg)
FITC MNPs
supernatant 44.48 9.94×10
-8 4.63×10-8 1.80×10-2
FITC MNPs 7866 2.62×10-5 6.36×10-6 2.48
TABLE 3:  Quantification of SNP molecules within the nanoparticles.
[SNP] Soaking 
mol dm-3
[SNP] Supernatant 
mol dm-3
[SNP] loading 
mol dm-3
MNPs 1 x 10-5 0.137 x 10-5 0.863 x 10-5
FITC MNPs 1 x 10-5 0.0354 x 10-5 0.966 x 10-5
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TABLE 4: One-way Anova with Bonferroni correction for relaxation of aortic 
vessels due to incubation in MNP and MNP loaded SNP with and without dye 
encapsulation (where NS=not significant, *=p<0.05, **=p<0.01 and ***=p<0.001).  
Time 
(min)
Significance difference in relaxation in comparison to KPSS control
MNPs MNPs + SNP FITC MNPs FITC MNPs + SNP
1 NS ** NS ***
2 NS *** NS ***
3 NS *** NS ***
4 NS *** NS ***
5 NS *** NS ***
6 NS *** NS ***
7 NS *** NS ***
8 NS *** NS ***
9 NS *** NS ***
10 NS *** NS ***
15 NS *** NS ***
20 NS *** NS ***
25 NS *** NS ***
30 NS *** NS ***
35 NS *** NS ***
40 NS *** NS ***
45 NS *** NS ***
50 NS *** NS ***
55 NS *** NS ***
60 NS *** * ***
65 NS *** * ***
70 NS *** * ***
75 NS *** * ***
80 NS *** * ***
85 NS *** * ***
90 NS *** * ***
95 NS *** NS ***
100 NS *** NS ***
105 NS *** NS ***
110 NS *** NS ***
115 NS *** NS ***
120 NS *** NS ***
125 NS *** NS ***
130 NS *** NS ***
135 NS *** NS ***
140 NS *** NS ***
145 NS *** NS ***
150 NS *** NS ***
155 NS *** NS ***
160 NS *** NS ***
165 NS *** NS ***
170 NS *** NS ***
175 NS *** NS ***
180 NS *** NS ***
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TABLE 5:  The concentration of SNP released from the MNP matrix in vitro, 
calculated from the logarithmic equation derived from the SNP control relaxation 
calibration graph.  
Time 
(min)
Concentration of SNP 
releases from the MNPs in  
vitro
Concentration of SNP 
releases from the FITC 
MNPs in vitro
1 8.82×10-10 6.09×10-09
2 3.25×10-09 1.71×10-08
3 5.08×10-09 2.32×10-08
4 7.62×10-09 2.50×10-08
5 1.00×10-08 3.14×10-08
6 1.52×10-08 3.42×10-08
7 1.75×10-08 4.02×10-08
8 2.19×10-08 5.28×10-08
9 2.57×10-08 5.56×10-08
10 3.17×10-08 6.13×10-08
15 5.84×10-08 1.12×10-07
20 8.97×10-08 1.38×10-07
25 1.23×10-07 1.72×10-07
30 1.52×10-07 1.73×10-07
35 1.77×10-07 1.74×10-07
40 2.19×10-07 1.74×10-07
45 2.33×10-07 1.62×10-07
50 2.76×10-07 1.47×10-07
55 3.05×10-07 1.23×10-07
60 3.60×10-07 1.23×10-07
65 3.76×10-07 1.17×10-07
70 4.04×10-07 1.16×10-07
75 4.62×10-07 1.19×10-07
80 4.44×10-07 1.07×10-07
85 5.21×10-07 1.05×10-07
90 5.63×10-07 1.08×10-07
95 5.50×10-07 8.35×1008
100 5.67×10-07 7.59×10-08
105 6.22×10-07 6.94×10-08
110 6.20×10-07 7.27×10-08
115 6.52×10-07 9.48×10-08
120 6.16×10-07 8.60×10-08
125 6.62×10-07 7.36×10-08
130 6.53×10-07 7.19×10-08
135 6.01×10-07 6.63×10-08
140 6.21×-07 6.67×-08
145 6.13×-07 7.23×-08
150 5.55×-07 5.74×-08
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155 6.15×-07 5.54×-08
160 5.97×-07 5.27×-08
165 5.28×10-07 4.86×-08
170 5.42×-07 4.86×-08
175 5.09×-07 4.64×-08
180 4.91×-07 4.51×-08
TABLE 6:  The total concentration of SNP released from the MNP matrix, in vitro  
after 180 mins.  
MNPs FITC MNPs
Total SNP released in the in 
vitro study (mol dm-3) a 4.91×10
-7 0.451×10-7
SNP released from MNP after 
(mol dm-3)γ 9.99 ×10
-7 1.66 ×10-7
a Calculated from the  in vitro control studies of SNP.
γ Determined from atomic absorption spectroscopy.
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